|1.||Wang, Ena: 1 article (06/2005)|
|2.||Smith, Kina: 1 article (06/2005)|
|3.||Marincola, Francesco M: 1 article (06/2005)|
|4.||Basil, Christopher: 1 article (06/2005)|
|5.||Nagorsen, Dirk: 1 article (06/2005)|
|6.||Deola, Sara: 1 article (06/2005)|
|7.||Stroncek, David F: 1 article (06/2005)|
|8.||Panelli, Monica C: 1 article (06/2005)|
|9.||Aricó, Eleonora: 1 article (06/2005)|
|10.||Mostafa, M G: 1 article (12/2000)|
07/01/1994 - "KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to ADM, and also has demonstrated an antitumor effect on ADM-resistant tumors. "
03/01/1990 - "In preclinical studies, KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to adriamycin. "
|2.||Breast Neoplasms (Breast Cancer)
08/01/1993 - "MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial."
08/01/1993 - "We performed a preliminary phase II clinical trial of MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in patients with metastatic breast cancer who had failed to respond to previous chemotherapeutic regimens after clinical evidence of systemic disease. "
12/01/2000 - "Tumor growth was inhibited by 32.4% with DOX despite a tendency (p < 0.16) and by 59.4% with MX-2 (p < 0.001); neither of these drugs resulted in complete tumor regression. "
12/01/1991 - "The pharmacokinetic properties of KRN 8602, an anthracycline compound, was studied by HPLC following intravenous administration of KRN 8602 to cancer patients. "
12/01/1991 - "[Pharmacokinetics of KRN 8602 in cancer patients]."
08/01/1989 - "MX-2 was active even against ADM-resistant cancer cells. "
05/01/1988 - "The increased life span was 40, 40, 40 (p less than 0.01), and 20% (p less than 0.05) in the animals given intravenous MX-2 of 1.5, 1.0, 0.75, and 0.375 mg/kg on day 1, 5, and 9 after tumor inoculation respectively. "
|4.||Brain Neoplasms (Brain Tumor)
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
08/01/1989 - "The antitumor activities of KT6149, MX-2 (KRN8602), SM5887, menogaril (TUT-7), and liblomycin (NK313) were evaluated against four non-small cell lung cancer cell lines, PC-7, -9, -13, and -14; two small cell lung cancer cell lines, H69 and N231; four CDDP-resistant cell lines, PC-7/1.0, PC-9/0.5, PC-14/1.5, and H69/0.4; a human myelogenous leukemia cell line, K562; and its ADM-resistant subline, K562/ADM by clonogenic assay. "